Pharmacological Treatment of Neuropathic Cancer Pain: A Comprehensive Review of the Current Literature

Pain Practice

Volumn 12, Issue 3, 2012, Pages 219-251

  Vadalouca, Athina ^a   Raptis, Efklidis ^b   Moka, Eleni ^c   Zis, Panagiotis ^d   Sykioti, Panagiota ^e   Siafaka, Ioanna ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b PFIZER INC   (United States)

^c Creta InterClinic Hospital (Private Sector)   (Greece)

^d EVANGELISMOS HOSPITAL   (Greece)

^e IASO GENERAL HOSPITAL   (Greece)

Author keywords

Adjuvants; Antidepressive agents; Cancer; Central nervous system agents; Chemotherapy; GABA; Opioid analgesics; Pain

Indexed keywords

AMFEBUTAMONE; ANTICONVULSIVE AGENT; CAPSAICIN; CARBAMAZEPINE; CARBOPLATIN; CISPLATIN; CITALOPRAM; CLONIDINE; DESIPRAMINE; DEXTROMETHORPHAN; DULOXETINE; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; LIDOCAINE; MEXILETINE; NORTRIPTYLINE; OXALIPLATIN; OXCARBAZEPINE; PAROXETINE; PREGABALIN; TAXANE DERIVATIVE; TIAGABINE; TOPIRAMATE; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE; VINCA ALKALOID; ZONISAMIDE;

ADD ON THERAPY; ADJUVANT THERAPY; ANALGESIA; BEDTIME DOSAGE; BREAST CANCER; CANCER PAIN; CARDIOVASCULAR RISK; CHRONIC PAIN; COLON CANCER; CONSTIPATION; DIAGNOSTIC IMAGING; DIARRHEA; DISEASE ASSOCIATION; DIZZINESS; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; ELECTRONEUROGRAPHY; EVOKED SOMATOSENSORY RESPONSE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERHIDROSIS; HYPERTENSION; LIVER TOXICITY; LUNG CANCER; LYMPHOMA; MONOTHERAPY; NAUSEA; NEUROPATHIC PAIN; NEUROPHARMACOLOGY; NONHUMAN; ORTHOSTATIC HYPOTENSION; OVARY CANCER; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; POSITRON EMISSION TOMOGRAPHY; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SKIN BIOPSY; SOMNOLENCE; STOMACH CANCER; TESTIS CANCER; WEIGHT GAIN; XEROSTOMIA;

EID: 84858004307     PISSN: 15307085     EISSN: 15332500     Source Type: Journal    
DOI: 10.1111/j.1533-2500.2011.00485.x     Document Type: Review

References (288)

1. Woolf CJ, Max MB. Mechanism-based pain diagnosis: issues for analgesic drug development. Anesthesiology. 2001;95:241-249.
2. McCleskey EW, Gold MS. Ion channels of nociception. Annu Rev Physiol. 1999;61:835-856.
3. Woolf CJ, Salter MW. Neuronal plasticity: increasing the gain in pain. Science. 2000;288:1765-1768.
4. Mogil JS, Yu L, Basbaum AI. Pain genes? Natural variation and transgenic mutants. Annu Rev Neurosci. 2000;23:777-811.
5. Woolf CJ, Bennet GJ, Doherty M, et al. Towards a mechanism based classification of pain? Pain. 1998;77:227-229.
6. Woolf CJ, Mannion RJ. Neuropathic pain: aetiology, symptoms, mechanisms and management. Lancet. 1999;353:1959-1964.
7. Urch CE, Dickenson AH. Neuropathic pain in cancer. Eur J Cancer. 2008;44:1091-1096.
8. Bostrom B, Sandh M, Lundberg D, Fridlund B. A comparison of pain and health - related quality of life between two groups of cancer patients with differing average levels of pain. J Clin Nurs. 2003;12:726-735.
9. Williams LS, Jones WJ, Shen J, Robinson RL, Weinberger M, Kroenke K. Prevalence and impact of depression and pain in neurology outpatients. J Neurol Neurosurg Psychiatry. 2003;74:1589-1599.
10. Caraceni APR, Portenoy RK. IASP task force: an international survey of cancer pain characteristics and syndromes. Pain. 1999;82:263-274.
11. Grond S, Radbruch L, Meuser T, Sabatowski R, Loick G, Lehmann KA. Assessment and treatment of neuropathic cancer pain following WHO guidelines. Pain. 1999;79:15-20.
12. Mantyh PW, Clohisy DR, Koltzenburg M, Hunt SP. Molecular mechanisms of cancer pain. Nat Rev. 2002;2:201-209.
13. Honore P, Rogers SD, Schwei MJ, et al. Murine models of inflammatory, neuropathic and cancer pain each generates a unique set of neurochemical changes in the spinal cord and sensory neurons. Neuroscience. 2000;98:585-598.
14. Cain DM, Wacnik PW, Turner M, et al. Functional interactions between tumor and peripheral nerve: changes in excitability and morphology of primary afferent fibers in a murine model of cancer pain. J Neurosci. 2001;21:9367-9376.
15. Wacnik PW, Eikmeier LJ, Ruggles TR, et al. Functional interactions between tumor and peripheral nerve: morphology, algogen identification and behavioral characterization of a new murine model of cancer pain. J Neurosci. 2001;21:9355-9366.
16. Bennett MI, Smith BH, Torrance N, Lee AJ. Can pain be more or less neuropathic? Comparison of symptom assessment tools with ratings of certainty by clinicians. Pain. 2006;122:289-294.
17. Besson JM. The neurobiology of pain. Lancet. 1999;353:1610-1615.
18. Shimoyama M, Tatsuoka H, Ohtori S, Tanaka K, Shimoyama N. Change of dorsal horn neurochemistry in a mouse model of neuropathic cancer pain. Pain. 2005;114:221-230.
19. Flatters SJ, Bennett GJ. Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: evidence for mitochondrial dysfunction. Pain. 2006;122:245-257.
20. Donovan-Rodriguez T, Dickenson AH, Urch CE. Gabapentin normalizes spinal neuronal responses that correlate with behaviour in a rat model of cancer - induced bone pain. Anesthesiology. 2005;102:132-140.
21. Paice JA. Mechanisms and management of neuropathic pain in cancer. J Support Oncol. 2003;1:107-120.
22. Foley KM. Opioids and chronic neuropathic pain. N Engl J Med. 2003;348:1279-1280.
23. Sarantopoulos CD. Advances in the therapy of cancer pain: from novel experimental models to evidence-based treatments. Signa Vitae. 2007;2(suppl 1):S23-S41.
24. Chong MS, Bajwa ZH. Diagnosis and treatment of neuropathic pain. J Pain Symptom Manage. 2003;25:S4-S11.
25. Merskey H, Bogduk N. Classification of chronic pain, 2nd ed. Seattle: IASP Press; 1994.
26. IASP (International Association for the Study of Pain). IASP Pain Terminology.
27. Polomano RC, Farrar T. Pain and neuropathy in cancer survivors. Am J Nurs. 2006;106(suppl 3):39-47.
28. Cruccu G, Anand P, Attal N, et al. EFNS guidelines on neuropathic pain assessment. Eur J Neurol. 2004;11:153-162.
29. Hansson P. Neuropathic pain: clinical characteristics and diagnostic workup. Eur J Pain. 2002;6(A):47-50.
30. Treede DR, Jensen ST, Cambell NJ, et al. Neuropathic pain: redifinition and a grading system for clinical and research purposes. Neurology. 2008;70:1630-1635.
31. Meyer-Roseberg K, Burckhardt CS, Kvarnstrom A, Nordfors LO, Kristofferson A. A comparison of the SF - 36 and Nottingham Health Profile in patients with chronic neuropathic pain. Eur J Pain. 2001;5:391-403.
32. Meyer- Roseberg K, Kvarnstrom A, Kinnman E, Gordh T, Nordfors LO, Kristofferson A. Peripheral neuropathic pain - a multidimensional burden for patients. Eur J Pain. 2001;5:379-389.
33. Smith TE, Chong MS. Neuropathic pain. Hosp Med. 2000;61:760-766.
34. Bowsher D. Neurogenic pain syndromes and their management. Br Med Bull. 1991;47:644-666.
35. Carter GT, Galer BS. Advances in the management of neuropathic pain. Phys Med Rehabil Clin North Am. 2001;12:447-459.
36. Sunderland S. Brachial plexus injuries. Clin Neurol Neurosurg. 1993;95(S):S1-S2.
37. Boivi J. Central pain. In: Wall PD, Melzak R, eds. Textbook of Pain. Edinburgh: Churchill Livingstone;1999: 879-914.
38. Bonica JJ. Introduction: semantic, epidemiologic and educational issues. In: Casey KL, ed. Pain and central nervous system disease: The central pain syndromes. New York, NY: Raven Press; 1991:13-29.
39. Andersen G, Vestergaard K, Ingeman-Nielsen M, Jensen TS. Incidence of central post - stroke pain. Pain. 1995;61:187-193.
40. Cruccu G, Truini A. Neuropathic pain and its assessment. Surg Oncol. 2010;19:149-154.
41. Niv D, Devor M. Refractory neuropathic pain: the nature and extend of the problem. Pain Pract. 2006;6:3-9.
42. Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain. 1997;69:1-18.
43. Mercadante S, Arcuri E. Breakthrough pain in cancer patients: pathophysiology and treatment. Cancer Treat Rev. 1998;24:425-432.
44. Portenoy RK, Lesage P. Management of cancer pain. Lancet. 1999;353:1695-1700.
45. Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain. 1999;81:129-134.
46. NIH. NIH State of the Science Statement on symptom management in cancer: pain, depression and fatigue. NIH Consens State Sci Statements. 2002;19:1-29.
47. Kreefe FA, Abernethy AP, Campbell CL. Psychological apaproaches to understanding and treating disease related pain. Ann Rev Psychol. 2005;56:1-22.
48. Forman AD. Peripheral neuropathy and cancer. Curr Oncol Rep. 2004;6:20-25.
49. Christo PJ, Mazloomdoost D. Cancer pain and analgesia. Ann NY Acad Sci. 2008;1138:278-298.
50. Bonica J. The management of pain, Vol I. Philadelphia: Lea & Febiger;1990.
51. ESMO. Management of cancer pain: clinical Recommendations. Ann Oncol. 2007;18(suppl 2):ii92-ii94.
52. Meuser T, Pietruck C, Radbruch L, Stute P, Lehmann KA, Grond S. Symptoms during cancer pain treatment following WHO Guidelines: a longitudinal follow up study of symptom prevalence, severity and etiology. Pain. 2001;93:247-257.
53. de Wit R, van Dam F, Loonstra S, et al. The Amsterdam Pain Management Index compared to eight frequently used outcome measures to evaluate the adequacy of pain treatment in cancer patients with chronic pain. Pain. 2001;91:339-349.
54. Grond SZD, Diefenbach C, Radburch L, Lehman KA. Assessment of cancer pain: a prospective evaluation in 2266 cancer patients referred to a pain service. Pain. 1996;64:107-114.
55. Hansson PT, Lacerenza M, Marchettini P. Aspects of clinical and experimental neuropathic pain: the clinical perspective. In: Hansson PT, Fields HL, Hill RG, Marchettini P, eds. Neuropathic Pain: Pathophysiology and Treatment, Progress in Pain Research and Management. Seattle: IIASP Press, 2001;21:1-18.
56. Garcia de Paredes, del Moral Gonzalez, Martinez de Prado, et al. First evidence of oncologic neuropathic pain prevalence after screening 8615 cancer patients. Results of the on study. Ann Oncol. 2011;22:924-930.
57. Mantyh PW. Cancer pain and its impact on diagnosis, survival and quality of life. Nat Rev Neurosci. 2006;7:797-809.
58. Olsen NK, Pfeiffer P, Mondrup K, Rose C. Radiation-induced brachial plexus neuropathy in breast cancer patients. Acta Oncol. 1990;29:885-890.
59. Manas A, Monroy JL, Ramos AA, et al. Prevalence of neuropathic pain in radiotherapy oncology units. Int J Radiat Oncol Biol Phys. 2010. September 8 [epub ahead of print]. DOI:
60. Ververs JM. Risks, severity and predictors of physical and psychological morbidity after axillary lymph node dissection for breast cancer. Eur J Cancer. 2001;37:991-999.
61. Delaney A, Fleetwood-Wlker SM, Colvin La, Fallon M. Translational medicine: cancer pain mechanisms and management. Br J Anaesth. 2008;101:87-94.
62. Bruera E, Kim HN. Cancer pain. JAMA. 2003;290:2476-2479.
63. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 2001;27:165-176.
64. Coleman RE, Rubens RD. The clinical course of bone metastasis from bone cancer. Br J Cancer. 1987;55:61-66.
65. Coleman RE, Rubens RD. Bone metastasis and bone cancer. Cancer Treat Rev. 1985;12:251-270.
66. Portenoy RK. Mechanisms of clinical pain. Observations and speculations. Neurol Clin North Am. 1989;7:205-230.
67. Loeser J. In Bonica's Management of Pain, 3rd ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2001:19-21.
68. Banning A, Sjogren P, Henriksen H. Treatment outcome in a multidisciplinary cancer pain clinic. Pain. 1991;47:129-134.
69. Caraceni A, Mertini C, Zecca E, et al. Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliat Med. 2004;18:177-183.
70. Colvin L, Fallon M. Challenges in cancer pain management. Eur J Cancer. 2008;44:1083-1090.
71. Windebank AJ, Grisold W. Chemotherapy-induced neuropathy. J Periph Nerv Syst. 2008;13:27-46.
72. Regan JM, Peng P. Neurophysiology of cancer pain. Cancer Control. 2000;7:11-119.
73. Cleeland CS, Bennett GJ, Dantzer R, et al. Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer. 2003;97:2919-2925.
74. Henry DH, Viswanathan HN, Elkin EP, Traina S, Wade S, Cella D. Symptoms and treatment burden associated with cancer treatment: results from a cross-sectional national survey in the US. Support Care Cancer. 2008;16:791-801.
75. Portenoy R. Pain syndromes in patients with cancer and HIV/AIDS. In Portenoy R, ed. Contemporary Diagnosis and Management of Pain in Oncologic and AIDS Patients. 3rd ed. Newton, PA: Handbooks in Healthcare;2000;49-78.
76. Colleau SM. Neuropathic pain from chemotherapy in cancer: diagnosis and treatment dilemmas. Cancer Pain Release (WHO Pain and Palliative Care Communication Programs) 2008;21. Nos 1& 2.
77. Kaley TJ, Deangelis LM. Therapy of chemotherapy-induced peripheral neuropathy. Br J Haematol. 2009;145:3-14.
78. Loprinzi LC, Paice J. Neuropathic pain from chemotherapy in cancer: diagnosis and treatment dilemmas. Cancer Pain Release (WHO Pain and Palliative Care Communication Programs) 2008; 21. Nos 1 & 2.
79. Honore P, Schwei J, Rodgers SD, et al. Cellular and neurochemical remodeling of the spinal cord in bone cancer pain. Prog Brain Res. 2000;129:389-297.
80. Urch CE, Donovan-Rodriguez T, Dickenson AH. Alterations in dorsal horn neurons in a rat model of cancer-induced bone pain. Pain. 2003;106:347-356.
81. Bjurholm A, Kreicbergs A, Brodin E, et al. Substance P and CGRP: immunoreactive nerves in bone. Peptides. 1988;9:165-171.
82. Campa JA III, Payne R. The management of intractable bone pain: a clinician's perspective. Semin Nucl Med. 1992;22:3-10.
83. Hudson AJ. Pain perception and response: central nervous system mechanisms. Can J Neurol Sci. 2000;27:2-16.
84. Gebhart GF. Descending modulation of pain. Neurosci Biobehav Rev. 2004;27:729-737.
85. Irving G. Contemporary assessment and management of neuropathic pain. Neurology. 2005;64(suppl 3):S21-S27.
86. Vadalouca A, Siafaka I, Ergyra E, Vrachnou E, Moka E. Therapeutic management of chronic neuropathic pain. An examination of pharmacological treatment. Ann NY Acad Sci. 2006;1088:164-186.
87. Dworking RH, Backonja M, Rowbotham MC, Allen RR, Hewitt DJ, Loeser JD. Advances in neuropathic pain: diagnosis, mechanisms and treatment recommendations. Arch Neurol. 2003;60:1524-1535.
88. Truini A, Panuccio G, Galeotti F, et al. Laser evoked potentials as a tool for assessing the efficacy of antinociceptive drugs. Eur J Pain. 2010;14:222-225.
89. Wilkie DJ, Huang HY, Reilly N, Cain KC. Nociceptive and neuropathic pain in patients with lung cancer: a comparison of pain quality descriptors. J Pain Symptom Manage. 2001;22:899-910.
90. Potter J, Higginson IJ, Scadding JW, Quigley C. Identifying neuropathic pain in patients with head and neck cancer: use of the Leeds assessment of neuropathic symptoms and signs scale. J R Soc Med. 2003;96:379-383.
91. Mercadante S, Gebbia V, David F, et al. Tools for identifying cancer pain of predominantly neuropathic origin and opioids responsiveness in cancer patients. J Pain. 2009;10:594-600.
92. Vadalouca A, Demosthenous E, Raptis E, Siafaka I, Argyra E. The use of DN4 questionnaire for the diagnosis of neuropathic cancer pain. Mykonos, Greece: International Symposium of WIP, "ALGOS 2009", 2009. Abstract Book, pp 59.
93. Beniczky S, Tajti J, Timea Varga E, Vescei L. Evidence-based pharmacological treatment of neuropathic pain syndromes. J Neural Transm. 2005;112:735-749.
94. Finnerup NB, Johannesen IL, Sindrup SH, Bach FW, Jensen TS. Pain and dysaesthesia in patients with spinal cord injury: a postal survey. Spinal Cord. 2001;39:256-262.
95. Richeimer SH, Bajwa ZH, Kahraman SS, Ransil BJ, Warfield LA. Utilization patterns of tricyclic antidepressants in a multidisciplinary pain clinic: a survey. Clin J Pain. 1997;13:324-329.
96. Orza F, Boswell MV, Rosenberg SK. Neuropathic pain: review of mechanisms and pharmacologic management. NeuroRehabilitation. 2000;14:15-23.
97. Boulton AJM, Gries FA, Jervell JA. Guidelines for the diagnosis and outpatient management of diabetic peripheral neuropathy. Diabet Med. 1998;15:508-514.
98. Page JC, Chen EY. Management of painful diabetic neuropathy. A treatment algorithm. J Am Podiatr Med Assoc. 1997;87:370-379.
99. Perkin GD. Trigeminal neuralgia. Curr Treat Options Neurol. 1999;1:458-465.
100. Namaka M, Gramlich CR, Ruhlen D, Melanson M, Sutton I, Major J. A treatment algorithm for neuropathic pain. Clin Ther. 2004;26:951-979.
101. Semenchunk MR, Sherman S. Effectiveness of tizanidine in neuropathic pain: an open-label study. J Pain. 2000;1:285-292.
102. Takahashi H, Miyazaki M, Nanbu T, Yanagida H, Morita S. The NMDA-receptor antagonist ketamine abolishes neuropathic pain after epidural administration in a clinical case. Pain. 1998;75:391-394.
103. Mac Pherson RD. New directions in pain management. Drugs Today (Barc). 2002;38:135-145.
104. Attal N, Cruccu G, Haanpaa M, et al. EFNS Guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol. 2006;13:1153-1169.
105. Dworkin RH, O' Connor AB, Backonja M, et al. Pharmacological management of neuropathic pain: evidence-based recommendation. Pain. 2007;132:237-251.
106. Attal N, Cruccu G, Baron R, et al. EFNS Guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2011;17:1113-1123.
107. Walker VA, Hoskin PJ, Hanks GW, White ID. Evaluation of WHO analgesic guidelines for cancer pain in a hospital-based palliative care unit. J Pain Symptom Manage. 1988;3:145-149.
108. Ventafridda V, Tamburini M, Caraceni A, De COnno F, Naldi F. A validation study of the WHO method for cancer pain relief. Cancer. 1987;59:850-856.
109. Quasthoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy. J Neurol. 2002;249:9-17.
110. Ashburn MA, Lipman AG. Management of pain in the cancer patient. Anesth Analg. 1993;76:402-416.
111. Laird B, Colvin L, Fallon M. Management of cancer pain: basic principles and neuropathic cancer pain. Eur J Cancer. 2008;44:1078-1082.
112. Mercadante S, Fulfaro F, Casuccio A, Barresi L. Investigation of an opioid response categorization in advanced cancer patients. J Pain Symptom Manage. 1999;18:347-352.
113. Colvin L, Forbes K, Fallon M. Difficult pain. BMJ. 2006;332:1081-1083.
114. Fallon MT, Hanks GW. Opioid-resistant pain: sense or nonsense? The Pain Clin. 1993;6:205-206.
115. Knotkova H, Pappagallo M. Adjuvant analgesics. Med Clin North Am. 2007;91:113-124.
116. Guindon J, Walczak JS, Beaulieu P. Recent advances in the pharmacological management of pain. Drugs. 2007;67:2121-2133.
117. Fallon M, Hanks G, Cherny N. Principles of control of cancer pain. BMJ. 2006;332:1022-1024.
118. Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH. Algorithm for neuropathic pain treatment: an evidence-based proposal. Pain. 2005;118:289-305.
119. McGeeney BE. Adjuvant agents in cancer pain. Clin J Pain. 2008;24(suppl 10):S14-S20.
120. Arbaiza D, Vidal O. Tramadol in the treatment of neuropathic cancer pain: a double-blind, placebo-controlled study. Clin Drug Investig. 2007;27:75-83.
121. Attal N. Neuropathic Pain Special Interest Group of the International Association for the Study of Pain (IASP). Ann Oncol. 2010;21:1134-1135.
122. Hardy JR, Rees EA, Gwilliam B, Ling J, Broadley H, A' Hern R. A phase II study to establish the efficacy and toxicity of sodium valproate in patients with cancer-related neuropathic pain. J Pain Symptom Manage. 2001;21:204-209.
123. Jost L, Rollia F. ESMO Guidelines Working Group. Management of cancer pain: ESMO clinical recommendations. Ann Oncol. 2009;20(suppl 4):170-173.
124. Beydoun A, Backogna MM. Mechanistic stratification of antineuralgic agents. J Pain Symptom Manage. 2003;25:S18-S30.
125. Sanchez C, Hyttel J. Comparison of the effects of antidepressants and their metabolites on the reuptake of biogenic amines and on receptor binding. Cell Mol Neurobiol. 1999;19:467-489.
126. Max MB. Thirteen consecutive well designed randomized trial show that antidepressants reduce pain in diabetic neuropathy and post herpetic neuralgia. Pain Forum. 1995;4:248-253.
127. McQuay HJ, Tramer M, Nye BA, et al. A systematic review of antidepressants in neuropathic pain. Pain. 1996;68:217-227.
128. Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain. 1999;83:389-400.
129. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev. 2007;4:CD005454.
130. Cohen HW, Gibson G, Alderman MH. Excess risk of myocardial infarction in patients treated with antidepressant medication: association with use of tricyclic agents. Am J Med. 2000;108:2-8.
131. Hammack JE, Michalak JC, Loprinzi CL, et al. Phase III evaluation of nortryptiline for alleviation of symptoms of cisplatin-induced peripheral neuropathy. Pain. 2002;98:195-203.
132. Mercadante S, Arcuri E, Tirelli W, et al. Amitryptiline in neuropathic cancer patients in morphine therapy: a randomized, placebo-controlled, double-blind, crossover study. Tumori. 2002;88:239-242.
133. Semenchuk MR, Sherman S, Davis B. Double-blind, randomized, controlled trial of bupropion SR for the treatment of neuropathic pain. Neurology. 2001;57:1583-1588.
134. Sindrup SH, Bach FW, Madsen C, Gram LF, Jensen TS. Venlafaxine versus imipramine in painful polyneuropathy: a randomized-controlled trial. Neurology. 2003;60:1284-1289.
135. Rowbotham MC, Goli V, Kunz NR, et al. Venlafaxine-extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain. 2004;110:697-706.
136. Wernicke JF, Pritchett YL, D' Souza DN, et al. Duloxetin at doses of 60 mgr QD and 60 mgr BID is effective in treatment of diabetic neuropathic pain (DNP). [abstract] Neurology. 2004;62(supple 5): A192.
137. Kajdasz DK, Iyengar S, Desaiah D, et al. Duloxetine for the management of diabetic peripheral neuropathic pain: evidence-based findings from post hoc analysis of three multicentre, randomized, double-blind, placebo-controlled, parallel-group studies. Clin Ther. 2007;29(suppl):2536-2546. (Class I SR).
138. Veves A, Backonja M, Malik RA. Painful diabetic neuropathy: epidemiology, natural history, early diagnosis and treatment options. Pain Med. 2008;9:660-674.
139. Skljarevski V, Desaiah D, Zhang Q, et al. Evaluating the maintenance of effect of duloxetine in patients with peripheral neuropathic pain. Diabetes Metab Res Rev. 2009;25:623-631.
140. Sultan A, Gaskel H, Derry S, Moore RA. Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomized controleed trials. BMC Neurol. 2008;8:29. (1-9).
141. Tasmuth T, Hartel B, Kalso E. Venlafaxine in neuropathic pain following treatment of breast cancer. Eur J Pain. 2002;6:17-24.
142. Durand JP, Goldwasser F. Dramatic recovery of paclitaxel-disabling neurosensory toxicity following treatment with venlafaxine. Drugs. 2002;13:777-780.
143. Arm YM, Yousef AA. Evaluation of the efficacy of the administration of venlafaxine or gabapentin on acute and chronic post-mastectomy pain. Clin J Pain. 2010;26:381-385.
144. Bergouignan M. Cures heureuses de nevralgies facials essentielles par le diphenylhydantoinate de soude. Rev Laryngol Otol Rhinol. 1942;63:34-41.
145. Beydoun A. Symptomatic treatment of neuropathic pain: a focus on the role of anticonvulsants. Medscape CME Circle Lecture. 2001. Medscape CME Circle Lecture, (accessed October 9, 2005).
146. Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropahy in patients with diabetes mellitus: a randomized controlled trial. JAMA. 1998; 280: 1831-1836.
147. Rowbotham M, Harden N, Stacey B, et al. Gabapentin for the treatment of postherpetic neuralgia: a randomized, controlled trial. JAMA. 1998; 280: 1837-1842.
148. Sarantopoulos C, McCallum B, Kwok WM, Hogan Q. Gabapentin decreases membrane calcium currents in injured as well as in control mammalian primary afferent neurons. Reg Anesth Pain Med. 2002;27:47-57.
149. Patel MK, Gonzalez MI, Bramwell S, Pinnock RD, Lee K. Gabapentin inhibits excitatory synaptic transmission in the hyperalgesic spinal cord. Br J Pharmacol. 2000;130:1731-1734.
150. Backonja MM. Gabapentin monotherapy for the symptomatic treatment of painful neuropathy: a multicenter, double-blind, placebo-controlled trial in patients with diabetes mellitus. Epilepsia. 1999;40(suppl 6):S57-S59. discussion S73-S74.
151. Hayashida K, Obata H, Nakajima K, Eisenach JC. Gabapentin acts with the locus coeruleus to alleviate neuropathic pain. Anesthesiology. 2008;109:1077-1084.
152. Wodarski R, Clark AK, Marchand F, Malcangio M. Gabapentin reverses microglial activation in the spinal cord of streptozocin-induced diabetic rats. Eur J Pain. 2009;13:807-811.
153. Kim D, You B, Jo EK, Han SK, Simon MI, Lee SJ. NADPH oxidase 2-derived reactive oxygen species in spinal cord microglia contribute to peripheral nerve injury-induced neuropathic pain. Proc Natl Acas Sci USA. 2010;107:14851-14856.
154. Wiffen PJ. Gabapentin for acute and chronic pain. Cochrane Database Syst Rev. 2005;3:CD005452.
155. Wiffen PJ, Collins S, McQuay H, Carroll D, Jadad A, Moore A. Anticonvulsant drugs for acute and chronic pain. Cochrane Database Syst Rev. 2005;3:CD001133.
156. Gorson KC, Schott C, Herman R, Ropper AH, Rand WM. Gabapentin in the treatment of painful diabetic neuropathy: a placebo-controlled, double-blind, crossover trial. J Neurol Neurosurg Psychiatry. 1999;66:251-252.
157. Rice AS, Maton S. Gabapentin in postherpetic neuralgia: a randomized, double-blind, placebo controlled study. Pain. 2001;94:215-224.
158. Bone M, Critchley P, Buggy D Jr. Gabapentin in postamputation phantom limb pain: a randomized, double-blind, placebo-controlled, cross-over study. Reg Anesth Pain Med. 2002;27:481-486.
159. Pandey CK, Bose N, Carg G, et al. Gabapentin for the treatment of pain in Guillan-Barre syndrome: a double-blind, placebo-controlled, cross-over study. Anesth Analg. 2002;95:1719-1723.
160. Tai Q, Kirshblum S, Chen B, Milliss J, Johnston M, De Lisa JA. Gabapentin in the treatment of neuropathic pain after spinal cord injury: a prospective, randomized, double-blind, crossover trial. J Spinal Cord Med. 2002;25:100-105.
161. Van de Vusse AC, Stomp Van De Berg SGM, Kessels AHF, Weber WEJ. Randomized, controlled trial of gabapentin in complex regional pain syndrome type I. BMC Neurol. 2004;4:13-19.
162. Moka E, Katafygioti A, Argyra E, Siafaka I, Vadalouca A. The Role of Gabapentin as an Add-on Therapy in Chronic Neuropathic Pain [Abstract]. Tokyo: 11th International Pain Clinic WSPC, 2004, Abtracts Book, p. 188.
163. Serpell M. Gabapentin in neuropathic pain syndromes: a randomized, double-blind, placebo-controlled trial. Pain. 2002;99:557-566.
164. Caraceni A, Zecca E, Bonezzi C, et al. Gabapentin for neuropathic cancer pain: a randomized, controlled trial from the gabapentin cancer pain study group. J Clin Oncol. 2004;22:2909-2917.
165. Moka E, Stamatakis E, Vretakos G, Argyra E, Siafaka I, Vadalouca A. The Role of Gabapentin in Chronic Neuropathic Pain in MS Patients: A 4-Year Experience [Abstract]. Chile: 2nd International Symposium of Regional Anaesthesia and Pain Therapy; 2004.
166. Gilron I, Bailey JM, Tu D, Holden RR, Weaver DF. Morphine, gabapentin or their combination for neuropathic pain. N Engl J Med. 2005;352:1324-1334.
167. Shimoyama M, Shimoyama N, Hori Y. Gabapentin affects glutamatergic excitatory neurotransmission in the rat dorsal horn. Pain. 2000;85:405-414.
168. Alam M, Rabinowitz AD, Engler DE. Gabapentin treatment of multiple piloleiomyoma-related pain. J Am Acad Dermatol. 2002;46:S27-S29.
169. Bennett MI. Gabapentin significantly improves analgesia in people receiving opioids for neuropathic cancer pain. Cancer Treat Rev. 2005;31:58-62.
170. Bosnjak S, Jelic S, Susnjar S, Luki V. Gabapentin for relief of neuropathic pain related to anticancer treatment: a preliminary study. J Chemother. 2002;14:214-219.
171. Caraceni A, Zecca E, Martini C, De Conno F. Differences in gabapentin efficacy for cancer pain more apparent than real? J Pain Symptom Manage. 2001;21:93-94.
172. Chandler A, Williams JE. Gabapentin, an adjuvant treatment for neuropathic pain in a cancer hospital. J Pain Symptom Manage. 2000;20:82-86.
173. Devulder J, Lambert J, Naeyaert JM. Gabapentin for pain control in cancer patients' wound dressing care. J Pain Symptom Manage. 2001;22:622-626.
174. Keskinbora K, Pekel AF, Aydinli I. The use of gabapentin in a 12-year-old boy with cancer pain. Acta Anaesthesiol Scand. 2004;48:663-664.
175. Lossignol DA, Plehiers B, Body JJ. Gabapentin (Neurontin) and cancer pain: a pilot study. Rev Med Brux. 2004;25:429-435.
176. Mercadante S, Villari P, Fulfaro F. Gabapentin for opiod-related myoclonus in cancer patients. Support Care Cancer. 2001;9:205-206.
177. Oneschuk Dal-Shahri MZ. The pattern of gabapentin use in a tertiary palliative care unit. J Palliat Care. 2003;19:185-187.
178. Pelham A, Lee MA, Regnard CB. Gabapentin for coeliac plexus pain. Palliat Med. 2002;16:355-356.
179. Ripamonti C, Dickerson ED. Strategies for the treatment of cancer pain in the new millennium. Drugs. 2001;61:955-977.
180. Ross JR, Goller K, Hardy J, et al. Gabapentin is effective in the treatment of cancer-related neuropathic pain: a prospective, open-label study. J Palliat Med. 2005;8:1118-1126.
181. Ross JR, Waight C, Riley J, Broadley K. Gabapentin: resistant neuropathic pain and malignancy. Palliat Med. 2001;15:348-349.
182. Tsavaris N, Kopteridis P, Kosmas C, et al. Gabapentin monotherapy for the treatment of chemotherapy-induced neuropathic pain: a pilot study. Pain Med. 2008;9:1209-1216.
183. Bennett MI. Effectiveness of antiepileptic or antidepressant drugs when added to opioids for cancer pain: systematic review. Palliat Med. 2011;25:553-559.
184. Arai YC, Matsubara T, Shimo K, et al. Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine. J Anesth. 2010;24:407-410.
185. Mishra SH, Bhatnagar S, Gupta D, et al. Management of neuropathic cancer pain following the WHO analgesic ladder: a prospective study. Am J Hosp Palliative Care. 2009;25:447-451.
186. Stute P, Soukup J, Menzel M, Sabatowski R, Grond S. Analysis and treatment of different types of neuropathic cancer pain. J Pain Symptom Manage. 2003;26:1123-1131.
187. Bar Ad V. Gabapentin for the treatment of cancer-related pain syndromes. Rev Recent Clin Trials. 2010;5:174-178.
188. Dy SM. Evidence-based apaproaches to pain in advanced cancer. Cancer. 2010;16:500-506.
189. Yamama Y, Nishikawa K, Funao T, Mori T, Asada A. Intrathecal gabapentin and clonidine synergistically inhibit allodynia in spinal nerve-ligated rats. Life Sci. 2010;87:565-571.
190. Dworkin RH, Corbin AE, Young JD, et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized placebo-controlled trial. Neurology. 2003;60:1274-1283.
191. Rosenstock J, Tuchman M, La Moreaux L, Sharma U. Pregabalin for the treatment of painful, diabetic, peripheral neuropathy: a double-blind, placebo controlled trial. Pain. 2004;110:628-638.
192. Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ. Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev. 2009;3:CD007076.
193. Navarro A, Saldana MT, Perez C, Torrades S, Rejas J. Patient-reported outcomes in subjects with neuropathic pain receiving pregabalin: evidence from medical practice in primary care settings. Pain Med. 2010;11:719-731.
194. Vadalouca A, Raptis E, Moutzouri A, Stavropoulou E, Siafaka I, Argyra E. Pregabalin for the Management of Neuropathic Cancer Pain. Preliminary Results. Athens, Greece: Third International Congres on Neuropathic Pain of Neu PSIG; 2010, Abstract Book, p.73.
195. Eisenberg E, Lurie Y, Bracker C, Daond D, Ishay A. Lamotrigine reduces painful diabetic neuropathy: a randomized controlled study. Neurology. 2001;57:505-509.
196. Vestergaard K, Andersen G, Gottrup P, Kristensen BT, Jensen TS. Lamotrigine for central poststroke pain: a randomized controlled trial. Neurology. 2001;56:184-190.
197. Finnerup NB, Sindrup SH, Bach FW, Johannesen IL, Jensen TS. Lamotrigine in spinal cord injury pain: a randomized controlled trial. Pain. 2002;96:375-383.
198. Simpson DM, McArthur JC, Olney R, et al. A placebo controlled trial of lamotrigine for painful HIV-associated neuropathy. Neurology. 2000;54:2115-2119.
199. Macdonald J, Young LT. Newer antiepileptic drugs in bipolar disorder: rationale for use and role in therapy. CNS Drugs. 2002;16:549-562.
200. Vondracek P, Oslejkova H, Kepak T, et al. Efficacy of pregabalin in neuropathic pain in paediatric oncological patients. Eur J Paediatr Neurol. 2009;13:332-336.
201. Mattia C, Coluzzi F. Tramadol. Focus on musculoskeletal and neuropathic pain. Minerva Anaesthesiol. 2005;71:565-584.
202. Harati Y, Gooch C, Swenson M, et al. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology. 1998; 50:1842-1846.
203. Hollingshead J, Duhmke RM, Cornblath DR. Tramadol for neuropathic pain. Cochrane Database Syst Rev. 2006;3:CD003726.
204. Freeman R, Raskin P, Hewitt DJ, et al. Randomized study of tramadol/acetaminophen versus placebo in painful diabetic peripheral neuropathy. Curr Med Res Opin. 2007;23:147-161.
205. Boureau F, Legallicier P, Kabir Ahmadi M. Tramadol in post-herpetic neuralgia: a randomized double-blind placebo-controlled trial. Pain. 2003;104:323-331.
206. Sindrup SH, Andersen G, Madsen C, Smith T, Brosen K, Jensen TS. Tramadol relieves pain and allodynia in polyneuropathy: a randomized double-blind controlled trial. Pain. 1999;83:85-90.
207. Leppert W. Tramadol as an analgesic for mild to moderate cancer pain. Pharmacol Rep. 2009;61:978-992.
208. Gimbel JS, Richards P, Portenoy RK. Controlled-release oxycodone for pain in diabetic neuropathy. A randomized controlled trial. Neurology. 2003;60:927-934.
209. Watson CP, Watt- Watson J, Gordon A, Eisenhoffer J. Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain. 2003;105:71-78.
210. Watson CP, Babul N. Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. Neurology. 1998;50:1837-1841.
211. Huse E, Labrig W, Flor H, Birbaumer N. The effect of opioids on phantom limb pain and cortical reorganization. Pain. 2001;90:47-55.
212. Raja SN, Haythornthwaite JA, Pappagalo M, et al. Opioids versus antidepressants in postherpetic neuralgia. Neurology. 2002;59:1015-1021.
213. Morley JS, Bridson J, Nash JP, et al. Low-dose methadone has an analgesic effect in neuropathic pain: a double-blind randomized controlled crossover trial. Palliat Med. 2003;17:576-587.
214. Rowbotham MC, Twilling L, Davies PS, Taylor K, Mohr D, Reisner L. Oral opioid therapy for chronic peripheral and central neuropathic pain. N Engl J Med. 2003;348:1223-1232.
215. McQuay H. Opioids in pain management. Lancet. 1999;353:2229-2232.
216. Besse D, Lombard MC, Zakac JM, et al. Pre-and post-synaptic distribution of mu, delta and kappa opioid receptors in the superficial layers of the cervical dorsal horn of the rat spinal cord. Brain Res. 1990;521:15-22.
217. Dickenson AH. Spinal cord pharmacology of pain. Br J Anaesth. 1995;75:193-200.
218. Xu XJ, Puke MJC, Verge VMK, et al. Up-regulation of cholecystokinin in primary sensory neurons is associated with morphine insensitivity in experimental neuropathic pain in the rat. Neurosci Lett. 1993;152:129-132.
219. Stanfa LC, Sullivan AF, Dickenson AH. Alterations in neuronal excitability and the potency of spinal mu, delta and kappa opioids after carrageenan induced inflammation. Pain. 1992;50:345-354.
220. Suzuki R, Chapman V, Dickenson AH. The effectiveness of spinal and systemic morphine on rat dorsal horn neuronal responses in the spinal nerve ligation model of neuropathic pain. Pain. 1999;80:215-228.
221. Cherny NI, Thaler HT, Friedlander-Klar H, et al. Opioid responsiveness of cancer pain syndromes caused by neuropathic or nociceptive mechanisms. Neurology. 1994;44:857-861.
222. Indelicato RA, Portenoy RK. Opioid rotation in the management of refractory cancer pain. J Clin Oncol. 2002;20:348-352.
223. Vadalouca A, Moka E, Argyra E, Sykioti P, Siafaka I. Opioid rotation in patients with cancer: a review of the current literature. J Opioid Manage. 2008;4:213-250.
224. Eisenber E, McNicol ED, Carr DB. Efficacy of mu-opioids agonists in the treatment of evoked neuropathic pain: systematic review of randomized controlled trials. Eur J Pain. 2006;10:667-676.
225. Ong EC. Controlled-release oxycodone in the treatment of neuropathic pain of nonmalignant and malignant causes. Oncology. 2008;74(suppl 1):72-75.
226. Allen SC. Neuropathic pain - the case for opioids therapy. Oncology. 2008;74(suppl 1):76-82.
227. Gatti A, Sabato E, Di Paolo AR, Mammucari M, Sabato AF. Oxycodone/Paracetamol: a low dose synergic combination useful in different types of pain. Clin Drug Invest. 2010;30(suppl 2):3-14.
228. El Mouedden M, Meert TF. Evaluation of pain-related behaviour, bone destruction and effectiveness of fentanyl, sufentanyl, and morphine in a murine model of cancer pain. Pharmacol Biochem Behav. 2005;82:109-119.
229. Menendez L, Lastra A, Fresno MF, et al. Initial thermal heat hyperalgesia and delayed hyperalgesia in a murine model of bone cancer pain. Brain Res. 2003;969:102-109.
230. Sueoka N, Sueoka E, Okabe S, Fujiki H. Anti-cancer effects of morphine through inhibition of tumour necrosis factor-alpha release and mRNA expression. Carcinogenesis. 1996;17:2337-2341.
231. Ishikawa M, Tanno K, Kamo A, Takayanagi Y, Sasaki K. Enhancement of tumor growth by morphine and its possible mechanism in mice. Biol Pharm Bull. 1993;16:762-766.
232. Lewis JW, Shavit Y, Terman GW, Gale RP, Liebeskind JC. Stress and morphine affect survival of rats challenged with a mammary ascites tumor (MAT 13762B). Nat Immun Cell Growth Regul. 1983;3:43-50.
233. Wiffen PJ, Edward JE, Barden J, McQuay HJ. Oral morphine for cancer pain. Cochrane Database Syst Rev. 2003;4:CD003868.
234. Eisenberg E, McNicol ED, Carr DB. Efficacy and safety of opioid agonists in the treatment of neuropathic pain of non-malignant origin. JAMA, 2005;293:3043-3052.
235. Ballantyne J, Mao J. Opioid therapy for chronic pain. N Engl J Med. 2003;349:1943-1953.
236. Max MB, Schafer SC, Culnane M, et al. Association of pain relief with drug side effects in postherpetic neuralgia: a single dose study of clonidine, codeine, ibuprofen and placebo. Clin Pharmacol Ther. 1998;43:1427-1432.
237. McNicol E, Strassels SA, Goudas L, Lau J, Carr DB. NSAIDs or paracetamol, alone or combined with opioids, for cancer pain. Cochrane Database Syst Rev. 2005;1:CD005180.
238. Rowbotham MC, Davies PS, Verkempinck C, Galer BS. Lidocaine patch: double-blind, controlled study of a new treatment for post-herpetic neuralgia. Pain. 1996;65:39-44.
239. Galer BS, Rowbotham MC, Perander J, Friedman E. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. Pain. 1999;80:533-538.
240. Meier T, Wasner G, Faust M, et al. Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: a randomized, double-blind, placebo-controlled study. Pain. 2003;106:151-158.
241. Barbano RL, Herrmann DN, Hart-Gouleau S, Pennella-Vaughan J, Lodewick PA, Dworkin RH. Effectiveness, tolerability, and impact on quality of life of the 5% lidocaine patch in diabetic polyneuropathy. Arch Neurol. 2004;61:914-918.
242. Argyra E, Siafaka I, Moka E, Vadalouca A. 5% Lidocaine patch in the treatment of neuropathic pain of diverse origin [abstract]. Aachen: 9th Congress of the European Association for Palliative Care (EAPC), Eur J Pall Care, 2005, Abstracts Book, p.80.
243. Baron R, Mayoral V, Leijon G, Binder A, Steigerwald I, Serpell M. 5% Lidocaine patch medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority, two-stage, RCT study. Curr Med Res Opin. 2009;27:1663-1676.
244. Hans G, Sabatowski R, Binder A, Boesl I, Rogers P, Baron R. Efficacy and tolerability of a 5% lidocaine medicated plaster for the topical treatment of post-herpetic neuralgia: results of a long-term study. Curr Med Res Opin. 2009;25:1295-1305.
245. Hans GH, Robert DN, Van Maldeghem KN. Treatment of an acute severe central neuropathic pain syndrome by topical application of lidocaine 5% patch: a case report. Spinal Cord. 2008;46:311-313.
246. Cheville AL, Sloan JA, Northfelt DW, et al. Use of a lidocaine patch in the management of postsurgical neuropathic pain in patients with cancer: a phase III double-blind crossover study (N01CB). Support Care Cancer. 2009;17:451-460.
247. Backonja M, Wallace MS, Blonsky ER, et al. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomized, double-blind study. Lancet Neurol. 2008;12:1106-1112.
248. Backonja MM, Malan TP, Vanhove GF, Tobias JK. NG X-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomized, double-blind, controlled study with an open-label extension. Pain Med. 2010;4:600-608.
249. Simpson DM, Brown S, Tobias J. NGX - 4010 C107 Study Group. Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy. Neurology. 2008;70:2305-2313.
250. Ellison N, Loprinzi CL, Kugler J, et al. Phase III placebo-controlled trial of capsaicin cream in the management of surgical neuropathic pain in cancer patients. J Clin Oncol. 1997;15:2974-2980.
251. Paice JA, Ferrans CE, Lashley F, et al. Topical capsaicin in the management of HIV-associated peripheral neuropathy. J Pain Symptom Manage. 2000;19:45-52.
252. Noto C, Pappagalo M, Szallasi A. NGX - 4010, a high concentration capsaicin patch for lasting relief of peripheral neuropathic pain. Curr Opin Investig Drugs. 2009;10:702-710.
253. Kanner R. Diagnosis and management of neuropathic pain in patients with cancer. Cancer Invest. 2001;19:324-333.
254. Mercadante SL, Berchovich M, Casuccio A, Fulfaro F, Mangione S. A prospective randomized study of corticosteroids as adjuvant drugs to opioids in advanced cancer patients. Am J Hosp Palliat Care. 2007;24:13-19.
255. Novakovic SD, Tzoumaka E, McGivern JG, et al. Distribution of the tetrodoxin-resistant sodium channel PN3 in rat sensory neurons in normal and neuropathic conditions. J Neurosci. 1998;18:2174-2187.
256. Ferrini RL. Parenteral lidocaine for severe intractable pain in 6 hospice patients continued at home. J Palliat Med. 2001;3:193-201.
257. Trujillo KA, Akil H. Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science. 1991;251:85-87.
258. Mao J, Price DD, Caruso FS, Mayer DJ. Oral administration of dextromethorphan prevents the development of morphine tolerance and dependence in rats. Pain. 1996;67:361-368.
259. Mercadante S, Arcuri E, Tirelli W, Casuccio A. Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, cross-over, double-dose study. J Pain Symptom Manage. 2000;20:246-252.
260. Mitchell AC, Fallon MT. A single infusion of intravenous ketamine improves pain relief in patients with critical limb ischaemia: results of a double-blind, randomized, controlled trial. Pain. 2002;97:275-281.
261. Javery KB, Ussery TW, Steger HG, et al. Comparison of morphine and morphine with ketamine for postoperative analgesia. Can J Anaesth. 1996;43:212-215.
262. Pud D, Eisenberg E, Spitzer A, et al. The NMDA receptor antagonist amantadine reduces surgical neuropathic pain in cancer patients: a double-blind, randomized, placebo-controlled trial. Pain. 1998;75:349-354.
263. Okon T. Ketamine: an introduction for the pain and palliative medicine physician. Pain Physician. 2007;10:493-500.
264. Crosby V, Wilcock A, Corcoran R. The safety and efficacy of a single dose (500mg or 1g) of intravenous magnesium sulfate in neuropathic pain poorly responsive to strong opioid analgesics in patients with cancer. J Pain Symptom Manage. 2000;19:35-39.
265. Nikcevich DA, Grothey A, Sloan JA, et al. Effect of intravenous calcium and magnesium (IV Ca, Mg) on oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: results of the phase III, placebo-controlled, double-blind NCCTG trial N04C7. J Clin Oncol, 2008;26(suppl 15):p4009. [abstract].
266. Crain SM, Shen KF. Opioids can evoke direct receptor-mediated excitatory effects on sensory neurons. Trends Pharmacol Sci. 1990;11:77-81.
267. Crain SM, Shen KF. Antagonists of excitatory opioid receptor functions enhance morphine's analgesic potency and attenuate opioid tolerance/dependence liability. Pain. 2000;84:121-131.
268. Cruciani RA, Pasternak GW. Blockade of hyperalgesia by antisense oligodeoxynucleotide to Gsa. Seatle, WA: Program of the 31st International Narcotic Research Conference, July 15-20; 2000, Abstract Βοοκ, p. 59.
269. Kingery WS. A critical review of controlled trials for peripheral neuropathic pain and complex regional pain syndromes. Pain. 1997;73:123-139.
270. Gralow J, Tripathy D. Managing metastatic bone pain: the role of bisphosphonates. J Pain Symptom Manage. 2007;33:462-472.
271. Pavlakis N, Schmidt R, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev. 2005;3:CD003474.
272. Walker K, Medhurst SJ, Kidd BL, et al. Disease modifying and anti-nociceptive effects of the bisphosphonate zoledronic acid in a model of bone cancer pain. Pain. 2002;100:219-229.
273. Yuen KK, Shelley M, Sze WM, Wilt T, Mason MD. Bisphosphonates for advanced prostate cancer. Cochrane Database Syst Rev. 2006;4:CD006250.
274. Djulbegovic B, Wheatley K, Ross J, et al. Bisphosphonates in multiple myeloma. Cochrane Database Syst Rev. 2010;3:CD003188.
275. Gobelet C, Meier JL, Schaffner W, Bischof-Delaloye A, Gerster JC, Burckhardt P. Calcitonin and reflex sympathetic dystrophy syndrome. Clin Rheumatol. 1986;5:382-388.
276. Martin TJ. The therapeutic uses of calcitonin. Scott Med J. 1978;23:161-165.
277. Rifat SF, Kiningham RB, Peggs JF. Calcitonin in the treatment of osteoporotic bone pain. J Fam Pract. 1992;35:93-96.
278. Szanto J, Ady N, Jozsef S. Pain killing with calcitonin nasal spray in patients with malignant tumors. Oncology. 1992;49:180-182.
279. Martinez- Zapata MJ, Roque M, Alonso-Coello P, Catala E. Calcitonin for metastatic bone pain. Cochrane Database Syst Rev. 2006;3:CD003223.
280. Farrar JT, Portenoy RK. Neuropathic cancer pain: the role of adjuvant analgesics. Oncology. 2001;15:1435-1442.
281. Pace A, Carpano S, Galie E, et al. Vitamine E in the neuroprotection of cisplatininduced peripheral neurotoxicity and otoxicity. J Clin Oncol, 2007;25(suppl 18):p9114. [abstract].
282. Peat S. Using cannabinoids in pain and palliative care. Int J Palliat Nurs. 2010;16:481-485.
283. Cascinu S, Catalano V, Cordella L, et al. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2002;20:3478-3483.
284. Boyle FM, Wheeler HR, Shenfield GM. Glutamate ameliorates experimental vincristine neuropathy. J Pharmacol Exp Ther. 1996;279:410-415.
285. Hartrick CT, Rozek RJ. Tapentadol in pain management. CNS Drugs. 2011;25(5):359-370.
286. Hartrick CT. Tapentadol immediate-release for acute pain: a drug profile. Expert Rev Neurother. 2010;10:861-869.
287. Scwartz S, Etropolski M, Shapiro DY, et al. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. Curr Med Res Opin. 2011;27:151-162.
288. Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. Pain. 2010;150:573-581.